Onconetix (ONCO) Capital Expenditures (2022 - 2024)

Onconetix (ONCO) posted quarterly Capital Expenditures of $3874.0 for Q4 2024, up 67.49% quarter-over-quarter from $2313.0 in Q3 2024.

Onconetix (ONCO) Capital Expenditures (2022 - 2024) Analysis & Trends

Onconetix (ONCO) has reported Capital Expenditures for 3 consecutive years, with $3874.0 the latest figure, recorded in Q4 2024.

In Q4 2024, Capital Expenditures changed N/A year-over-year to $3874.0; the TTM figure through Dec 2024 stood at $28471.0 (down 99.53% YoY), while the FY2024 annual figure was $28471.0, down 99.53% from the prior year.
Capital Expenditures climbed to $3874.0 in Q4 2024 per ONCO's latest filing, from $2313.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $6.1 million in Q3 2023 and bottomed at $1481.0 in Q2 2023.
Historically, Capital Expenditures has averaged $614685.9 across 3 years, with a median of $4360.0 in 2022.
On a YoY basis, Capital Expenditures climbed as much as 1095.54% in 2024 and fell as far as 99.96% in 2024.
Onconetix's Capital Expenditures stood at $29278.0 in 2022, then soared by 20654.39% to $6.1 million in 2023, then plunged by 99.94% to $3874.0 in 2024.
Business Quant data shows ONCO's Capital Expenditures at $3874.0 in Q4 2024, $2313.0 in Q3 2024, and $17706.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Onconetix	1.44 Mn	-4.50 Mn	4,303.00	-

Download Data